DCTY 0801
Alternative Names: DCTY-0801; EGFRvIII CAR-T cell therapy - Beijing DCTY BiotechLatest Information Update: 29 Jun 2023
Price :
$50 *
At a glance
- Originator Beijing DCTY Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 12 Apr 2023 Preclinical trials in Glioblastoma in China (Parenteral) (before April 2023) (NCT05802693)
- 06 Apr 2023 Beijing DCTY Biotech plans a phase I trial for Glioblastoma (Recurrent, In adults, In the elderly) (Parenteral) (NCT05802693)